Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01157065 · ClinicalTrials.gov registry record · Phase 2
Evaluation of AL-78898A in Exudative Age-Related Macular Degeneration
A Phase 2 study of Exudative Age-Related Macular Degeneration, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 99
- Enrollment target
- 1
- Study location
NCT01157065: Completed Phase 2 study of Exudative Age-Related Macular Degeneration, sponsored by Alcon Research.
NCT01157065 is a Phase 2 study of Exudative Age-Related Macular Degeneration that has completed, run by Alcon Research. The registered enrollment target is 99 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (26% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01157065, a Phase 2 study of Exudative Age-Related Macular Degeneration, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 99 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary purpose of this study was to demonstrate a biological effect of AL-78898A, as measured by change (reduction) in central subfield (CSF) retinal thickness 4 weeks after a single intravitreal injection, as compared to LUCENTIS.
Primary Outcome
The thickness of the retina was measured using a non-invasive device that produces cross-sectional and 3D images of the eye. The reduction was calculated by subtracting Week 4 visit value from the Baseline value. A positive number indicates a reduction in thickness compared to baseline, whereas a negative number indicates an increase in thickness. An increase in thickness as compared to baseline may indicate a progression of the underlying disease.
Conditions Studied
Interventions
- DRUG Ranibizumab
- DRUG AL-78898A
Study Locations (1)
Texas
- Contact Alcon Call Center for Trial Locations - Fort Worth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2011-06 |
| Est. Completion | 2012-04 |
| Phase | Phase 2 |
What the finished NCT01157065 record still lists
NCT01157065 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 99 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (26% lower).
The record links to 1 condition, with Exudative Age-Related Macular Degeneration appearing as the primary indexed condition, and to 2 interventions - of which Ranibizumab is the first listed.
NCT01157065 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT01157065 about?
NCT01157065 is a clinical study titled "Evaluation of AL-78898A in Exudative Age-Related Macular Degeneration". The primary purpose of this study was to demonstrate a biological effect of AL-78898A, as measured by change (reduction) in central subfield (CSF) retinal thickness 4 weeks after a single intravitreal injection, as compared to LUCENTIS.
What is the current status of trial NCT01157065?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 99 participants. The study started on 2011-06. Estimated completion is 2012-04.
What conditions does trial NCT01157065 study?
This clinical trial studies the following conditions: Exudative Age-Related Macular Degeneration.
What interventions are being tested in trial NCT01157065?
The interventions under investigation include: Ranibizumab (DRUG), AL-78898A (DRUG).
Who is sponsoring clinical trial NCT01157065?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01157065 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Exudative Age-Related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01157065's enrollment target sits among peer trials
99 738th of 2000 higher than 1,258 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03965234 · 99 participants · Phase 1
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
- NCT04022616 · 99 participants
Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients
- NCT04042844 · 99 participants · Phase 2
A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)
- NCT04143724 · 99 participants · Phase 2
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia